Alumis (ALMS) stock jumps as insider filings show $17 buys — what investors are watching next
Alumis Inc shares rose about 9% to $24.11 by midday Wednesday after insider filings showed directors Srinivas Akkaraju and James B. Tananbaum bought nearly 1 million shares at $17 each last week. The moves followed positive Phase 3 results for the company’s psoriasis drug envudeucitinib and a $345 million stock offering.